Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?
2026-10-09 00:43
•Sara Appino •The Motley Fool
•••••••••• •••••• Axe Cap view
Pfizer Edges Out Bristol Myers Squibb for 2026
Pfizer offers a clearer path past patent losses and drug pricing challenges than Bristol Myers Squibb.
South African investors watching global pharma should lean towards Pfizer over Bristol Myers Squibb. Both companies are grappling with patent cliffs that erode revenue but Pfizer’s diversified pipeline, including fast-growing obesity treatments and an expanding vaccine portfolio, provides a clearer growth trajectory. Pfizer’s commitment to steady dividends is a plus, especially as many healthcare stocks face margin pressure from regulatory changes, like the US Inflation Reduction Act on drug pricing. Bristol Myers, despite some near-term momentum and brand strength in Eliquis, carries heavier medium-term risks with significant patent expiries and an ongoing $6.7 billion lawsuit clouding its outlook. For those with rand-based exposure, Pfizer’s relative stability might better withstand rand volatility against the dollar as USD/ZAR remains elevated amid global uncertainty. The only fly in the ointment is if Pfizer’s pipeline breakthroughs stall or regulatory hurdles intensify beyond expectations. this is just our opinion and not financial advice
Trim Bristol Myers Squibb exposure and add Pfizer selectively for a more stable post-patent story, while monitoring USD/ZAR for currency risk. Maintain vigilance on regulatory developments that could upend pharma valuations.
- PFE
- BMY
- USD/ZAR
- Regulatory drug pricing reforms tightening further
- Pipeline setbacks or clinical trial failures at Pfizer
6/10
The article compares Bristol Myers Squibb and Pfizer as healthcare investment options for 2026. Both face patent cliffs and regulatory pressures, but Pfizer is recommended as the better choice due to its clearer post-patent roadmap, growing non-COVID products, obesity drug positioning, and committed dividend protection. Bristol Myers Squibb shows near-term momentum improvements but faces longer-term revenue uncertainty from patent losses and drug pricing reforms.
Our take is based on reporting first published by The Motley Fool.